- Dr Li Ren, a senior CAR T therapy executive from Bristol-Myers Squibb, has joined Chimeric Therapeutics as the Vice President of Technical Operations.
- Dr Ren will oversee the process and analytical development of CLTX CAR T, which is a promising therapy to treat glioblastoma.
- At Celgene and Celgene Cellular Therapies, Dr Ren has worked for around 15 years to progress TCR, CART T and NK cell therapies to the clinic.
In what will further level up its cell therapy expertise, Clinical stage cell therapy company Chimeric Therapeutics Limited (ASX:CHM) has announced the appointment of Dr Li Ren as the Vice President of Technical Operations. Dr Lin previously served as a senior CAR T therapy executive at Bristol-Myers Squibb (BMS).
Dr Ren’s appointment seems to be a robust move aimed at bolstering the ongoing development of Chimeric’s CLTX CAR T cell therapy for treating patients with progressive and recurrent glioblastoma.
Meanwhile, the oncology firm, committed to bringing the promise of cell therapy to life for cancer patients, is also trialling CLTX CAR T therapy in patients with other solid tumours, including small cell lung cancer, colorectal cancer, melanoma, and prostate cancer.
Dr Ren brings extensive expertise to the table
Dr Ren has around 20 years of experience in developing and advancing cell therapy drug candidates from the preclinical stage through to commercial licensure.
Over the course of her career, Dr Ren has headed the process and analytical development of many allogeneic & autologous cell therapy products, including CAR T cells, TCR cells, NK cells and mesenchymal-like stem cells.
At BMS, Dr Ren most recently oversaw the technology transfers of Juno cell therapy pipeline products to BMS manufacturing facilities. In addition, she also provided technical support for both GMP manufacturing as well as quality control (QC) testing for enabling clinical trials.
Before joining BMS, Dr Ren had been spearheading the chemistry, manufacturing, and control (CMC) efforts at Celgene and Celgene Cellular Therapies (CCT) for around 15 years to advance CAR T, TCR and NK cell therapies to the clinic.
She also supported numerous IND submissions for pipeline products, greasing the wheels for clinical trials and designed and led process & analytical validation programs favouring commercial registration filing.
Dr Ren’s appointment well-suited for Chimeric’s objective
Chimeric Therapeutics is actively engaged in improving its innovative cell therapies pipeline for cancer patients. The Company’s promising CLTX CAR T is currently undergoing the Phase 1 clinical trial at City of Hope.
Source: CHM Investor Presentation, dated 18 March 2021
At Chimeric, Dr Li Ren will be in charge of driving the process and analytical development of CLTX CAR T. She would also ensure successful technology transfer to CLTX CAR T clinical manufacturing organisation to facilitate future clinical trials.
Chimeric believes in the potential of cellular therapies to cure cancer by merging its expertise in developing and commercialising cell therapies with that of the most innovative scientists across the world.
CHM shares closed at A$0.280 on 25 June 2021.